Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Recent & Breaking News (GREY:SRNE)

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

GlobeNewswire January 18, 2022

Sorrento Therapeutics Mexico Wins Tender to Sell COVISTIX Tests to Mexico City Government

GlobeNewswire January 13, 2022

Sorrento Therapeutics Announces the Unexpected Death of its Chief Financial Officer

GlobeNewswire January 7, 2022

Dr. Henry Ji to Present at HC Wainwright BIOCONNECT Virtual Conference (January 10th - 13th)

GlobeNewswire January 7, 2022

Dr. Henry Ji to Participate in Longwood Healthcare Leaders Winter Webconference Panel on January 6th 2022

GlobeNewswire January 4, 2022

Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant

GlobeNewswire December 27, 2021

Sorrento Therapeutics Mexico Executes Second Contract for Sale of 10 Million COVISTIX Tests for Mexico Market

GlobeNewswire December 27, 2021

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

GlobeNewswire December 20, 2021

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA(TM)) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy

GlobeNewswire December 9, 2021

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)

GlobeNewswire December 7, 2021

Sorrento Therapeutics' Clinical Laboratory Receives Accreditation From the College of American Pathologists

GlobeNewswire December 7, 2021

Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil

GlobeNewswire December 6, 2021

Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) ("SPAC") Enter into Letter of Intent for Proposed Business Combination

GlobeNewswire December 6, 2021

Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron

GlobeNewswire December 5, 2021

Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference

GlobeNewswire November 30, 2021

Sorrento Publishes an Abivertinib Teaser Entitled "Abivertinib - A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases"

GlobeNewswire November 29, 2021

Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market

GlobeNewswire November 22, 2021

Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City

GlobeNewswire November 12, 2021

Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research

GlobeNewswire November 12, 2021

Sorrento Awarded California Competes Tax Credit

GlobeNewswire November 7, 2021